RDN2150

• Description :

  RDN2150 (Compound 25) is a ZAP-70 inhibitor (IC50: 14.6 nM) . RDN2150 covalently binds to the C346 residue of ZAP-70. RDN2150 inhibits the expression of CD25 and CD69, and inhibits CD4+ T cell activation. RDN2150 can be used for research of psoriasis[1].

• UNSPSC :

  12352005

• Target :

  Tyrosinase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/rdn2150.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=C(N=C(N2C1=NC=C2)NCC3=CC(NC(C=C)=O)=C(C=C3)Cl)NC4=CC(OC)=C(C=C4)N5CCOCC5)N

• Molecular Formula :

  C28H29ClN8O4

• Molecular Weight :

  577.03

• References & Citations :

  [1]Rao D, et al. Discovery and Structural Optimization of Covalent ZAP-70 Kinase Inhibitors against Psoriasis. J Med Chem. 2023 Aug 18.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2839429-51-3]